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Abstract
This study aimed to investigate prospective memory (PM) and the association with clinical
factors at 1-year follow-up in first-episode schizophrenia (FES). Thirty-two FES patients
recruited from a university-affiliated psychiatric hospital in Beijing and 17 healthy community
controls (HCs) were included. Time- and event-based PM (TBPM and EBPM) performances
were measured with the Chinese version of the Cambridge Prospective Memory Test (C-
CAMPROMPT) at baseline and at one-year follow-up. A number of other neurocognitive
tests were also administered. Remission was determined at the endpoint according to the
PANSS score 3 for selected items. Repeated measures analysis of variance revealed a
significant interaction between time (baseline vs. endpoint) and group (FES vs. HCs) for
EBPM (F(1, 44) = 8.8, p = 0.005) and for all neurocognitive components. Paired samples t-
tests showed significant improvement in EBPM in FES (13.1±3.7 vs. 10.3±4.8; t = 3.065,
p = 0.004), compared to HCs (15.7±3.6 vs. 16.5±2.3; t = -1.248, p = 0.230). A remission rate
of 59.4% was found in the FES group. Analysis of covariance revealed that remitters per-
formed significantly better on EBPM (14.9±2.6 vs. 10.4±3.6; F(1, 25) = 12.2, p = 0.002) than
non-remitters at study endpoint. The association between EBPM and 12-month clinical
improvement in FES suggests that EBPM may be a potential neurocognitive marker for the
effectiveness of standard pharmacotherapy. Furthermore, the findings also imply that PM
may not be strictly a trait-related endophenotype as indicated in previous studies.
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Introduction
Cognitive impairment is a core feature of schizophrenia [1–3]. A broad range of deficits in psy-
chomotor speed, memory, attention, reasoning, and social cognition have been reported [4].
Cognitive deficits usually exist even before the onset of illness [3, 5–8], worsen during the early
phase of schizophrenia [9], and persist throughout the whole life of patients, which, in turn,
influence functional outcomes [10, 11].
The course and trajectory of neurocognitive deficits in schizophrenia remain unclear. Over
time, they may deteriorate, show no significant change or even improve in certain cognitive
domains [12, 13]. The discrepancy between studies may be due to the heterogeneity of the ill-
ness and the types of treatment [14, 15].
A meta-analysis of longitudinal studies has found that schizophrenia patients showed less
improvement over time compared to controls in most cognitive variables except on the Stroop
Color-Word Test. These results suggest distinctive trajectories of changes in certain cognitive
components [13].
Prospective memory (PM) refers to remembering to perform a planned action or intention
at some future point in time [16]. PM is thought to play an important role to maintain daily
functioning. PM deficits have been consistently confirmed in both chronic [17–26] and first-
episode schizophrenia (FES) [27–29]. Non-psychotic first-degree relatives of schizophrenia
patients show similar but attenuated PM impairments compared to patients suggesting that
PM deficits may be an endophenotype of the illness [30].
There are two subtypes of PM: time-based (TBPM) and event-based PM (EBPM). In
EBPM, the carrying out of an intended action is prompted by an external cue, while TBPM
relies on the ability to perform an action at a specified time in the future [31]. PM is related to
prefrontal-lobe functions in both schizophrenia patients and their first-degree relatives, but
TBPM and EBPM may involve different neurocognitive processes [28, 30].
Longitudinal studies on PM changes in FES are important for a better understanding of the
pathophysiology of schizophrenia. Certain critical brain areas, such as the frontal pole, hippo-
campus, lateral prefrontal and inferior parietal regions, involved in PM impairment, have also
been reported to be abnormal in schizophrenia [32–38]. To the best of our knowledge, only
one follow-up study tracked PM changes over a one-year period finding that while TBPM
impairment was unchanged, EBPM significantly improved at the endpoint [39]. Because the
control group was not followed up, the impact of a differential practice effect on the results
could not be ruled out. It has been suggested that similar practice effects usually occur in both
control and clinical groups [40]. In order to control the potential practice effects, both patient
and control groups should be followed up [41].
The present study aimed to examine PM changes at one-year follow-up in both FES and
healthy controls, and explore their associations with demographic and clinical characteristics.
Methods
Participants and study setting
The study was conducted between January 2008 and December 2010 at the National Clinical
Research Centre of Mental Disorders located in Beijing Anding Hospital, an 800-bed univer-
sity-affiliated psychiatric center. Age-, gender- and education level-matched controls were
recruited from the community via media advertisement.
In- and out-patients receiving treatment for first-episode psychosis were consecutively
referred by their treating psychiatrists to the research team for screening of eligibility. Inclu-
sion criteria were (1) age between 16 and 45 years; (2) Chinese ethnicity; (3) at least six years of
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education; (4) first episode of the illness; (5) diagnosis of schizophrenia was made according to
the DSM-IV (APA, 1994) by two attending psychiatrists who administered the Structural Clin-
ical Interview for DSM-IV (SCID-DSM-IV; First et al., 1996), augmented by a chart review;
(6) ability to understand the aims of the study and the contents of the clinical interview and (7)
willingness to provide informed consent; (8) either antipsychotic treatment naïve or treatment
initiation of less than one month. Patients with a history of drug/alcohol abuse, ECT in the
past 12 months, medical or neurological condition(s), or mental retardation were excluded
from the study.
The study protocol was approved by the Clinical Research Ethics Committee of Beijing
Anding Hospital. Written consent was obtained prior to assessment from patients or their
family members for patients younger than 18 years of age as long as they verbally agreed to
participate.
Assessment
Basic socio-demographic and clinical characteristics were collected with a standard form
designed for this study by reviewing the charts supplemented by a clinical interview conducted
by a psychiatrist. Psychopathology was assessed using the Chinese version of the Positive and
Negative Syndrome Scale (PANSS; [42]). In this study, the following five clusters of the PANSS
were used: 1. Anergia (N1, N2, G7, G10); 2. Thought disturbance (P2, P3, P5, G9); 3. Activa-
tion (P4, G4, G5); 4. Paranoid/belligerence (P6, P7, G8); 5. Depression (G1, G2, G3, G6) [43].
Clinical remission was defined by a PANSS score = /<3 on each of the following items at the
endpoint of the study: delusions (P1), unusual thought contents (G9), hallucinatory behavior
(P3), conceptual disorganization (P2), mannerism/posturing (G5), blunted affect (N1), social
withdrawal (N4) and lack of spontaneity (N6) [44, 45].
The locally validated, Chinese version of the Cambridge PM Test (C-CAMPROMPT [46,
47] was used to assess PM functions for all participants. C-CAMPROMPT is an ecologically-
valid PM psychometric test that includes three TBPM and three EBPM tasks while performing
a few ongoing activities (i.e., a general knowledge quiz or word-finding puzzle) during a 20
minute period. Participants are allowed to use strategies, such as reminders to assist prospec-
tive remembering [48]. The C-CAMPROMPT generates scores on all six tasks, each scoring a
maximum of 6, thus the sum score ranges from 0 to 36.
Other neuropsychological assessments also included the following retrospective memory
and prefrontal lobe functions:
1. The Hopkins Verbal Learning Test-revised, Chinese version (HVLT-R; [49]) has three
learning trials (immediate recall) and a delayed recall subtest, for assessing retrospective
memory;
2. The Verbal Fluency Test, Chinese version (VFT; [49]) is composed of two character (pho-
nemic) and two category (sematic) tests; the sum of words produced in the two character
and two category trials is averaged and recorded separately;
3. The Color Trails Test (CTT; [49]) comprises two parts (CTT-1 and CTT-2), and is a “cul-
ture-fair” version of the Trail Making Test (TMT) for assessing sustained visual attention;
4. The Stroop Color Word Test Chinese version (SCWT; [49]) assesses selective attention
and cognitive flexibility; the Stroop Color—Word Interference score was used in this
study to measure the ability related to the suppression of a habitual response in favor of an
unusual one.
Prospective memory in schizophrenia
PLOS ONE | DOI:10.1371/journal.pone.0172114 February 28, 2017 3 / 13
Procedures
All FES patients were treated with antipsychotic monotherapy during the one-year study
period and only short-term (usually less than one week) injectable haloperidol was allowed
in agitated patients. For agitation, anxiety and insomnia, short-acting benzodiazepines were
used sparingly. In addition, low dose anticholinergic medication (trihexyphenidyl, maxi-
mum 6 mg/day) and propranolol were allowed to treat extrapyramidal side effects for any
length of time.
All the cognitive evaluation was conducted in a quiet room in the morning at the hospital.
In order to minimize the possibility of order effects, neurocognitive functions other than PM
were administered in a randomized order followed by the C-CAMPROMPT. All the cognitive
tests including C-CAMPROMPT were administered by a psychiatrist (FCZ) and a research
nurse who received training in using these instruments. Psychiatric symptoms were evaluated
by four other psychiatrists who were blinded to the patients’ performance on the cognitive
tasks. The inter-rater reliability exercise of the PANSS subscales yielded satisfactory agreement;
the intra-class correlation coefficients (ICC) ranged from 0.83 to 0.86.
Data analysis
All analyses were performed using SPSS Version 20.0. Comparisons between patients and con-
trols, and between clinically remitted patients and those who failed to remit (‘remitters’ and
‘non-remitters’, respectively) with regard to clinical variables were conducted by independent
sample t-test and Chi square test, as appropriate. Paired samples t-tests were used to compare
the neurocognitive variables including TBPM and EBPM between entry and endpoint in both
patients and controls.
Repeated measures analysis of variance (ANOVA) was performed for each cognitive test
with group (patient vs. control; remitters vs. non-remitters) as the between-group factor, and
time (baseline vs. 1-year) as the within-group factor. Effects of time, group, and the interaction
between time and group were examined. Cognitive domains that exhibited significant time-
group effects in patients and HCs were also examined using paired samples t-tests to investi-
gate longitudinal changes. In addition, analysis of covariance (ANCOVA) was performed in
the patient group comparing cognitive performance between remitters and non-remitters at
endpoint with age, gender, educational level and baseline PM score as covariates. All statistical
tests were two-tailed. Level of significance was set at the 0.05.
Results
Of the 55 FES patients screened for eligibility, 47 fulfilled entry criteria and participated in the
study, but only 40 completed all the assessments at baseline. Eight patients did not complete
the endpoint assessment due to lack of interest to continue participation. Patients who
dropped out did not differ significantly from those who completed the follow-up in terms of
age, gender and education level. Only the 32 patients who completed the endpoint assessment
at 1-year follow-up were included for analyses.
At baseline, 10 patients were drug-naive for antipsychotics, while the other 22 patients had
received less than 1 month of antipsychotic monotherapy with either risperidone, olanzapine,
aripiprazole, quetiapine, or haloperidol. No patients had received anticholinergic medications
before the study. Six patients received low dose (0.5mg-1mg daily) lorazepam before the study
entry.
Prospective memory in schizophrenia
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Comparison between patients and controls regarding longitudinal
changes in PM and other cognitive functions
Table 1 shows the basic demographic and clinical characteristics of the study sample by groups
at baseline and endpoint. At baseline, patients performed significantly poorer than controls
in TBPM (F(1,44) = 6.5, p = 0.014), EBPM (F(1,44) = 31.6 p<0.001), HVLT-R (F(1,44) = 6.2,
p = 0.017), CTT-1 (F(1,44) = 8.7, p = 0.005), SCWT (F(1,44) = 7.9, p = 0.007) and VFL (F(1,44) =
5.7, p = 0.021) after controlling for age, gender and educational level. At endpoint, patients’
score remained significantly lower than controls in TBPM (F(1,44) = 5.1, p = 0.029), EBPM
(F(1,44) = 6.3, p = 0.015), HVLT-R (F(1,44) = 7.0, p = 0.011), CTT-1(F(1, 44) = 18.9, p<0.001),
CTT-2 (F(1,44) = 12.4, p = 0.001), SCWT (F(1,44) = 8.8, p = 0.005), VFL (F(1,44) = 21.4, p<0.001)
and VFC (F(1,44) = 13.7, p = 0.001) after controlling for age, gender and education level.
In the patient group paired samples t-tests revealed significant changes from baseline to the
endpoint on TBPM, EBPM, HVLT-R and VFL scores. No difference was found between base-
line and endpoint assessments in the control group in any of the cognitive performances
including TBPM and EBPM.
After controlling for age, gender and education level, results of a repeated measures
ANOVA revealed significant time (baseline vs. endpoint)group (FES vs. HCs) interaction
only in EBPM (F(1,44) = 8.8, p = 0.005) (Table 1).
The association between clinical outcomes and neurocognitive
trajectories
Patients’ demographic and clinical characteristics and neurocognitive performance by remis-
sion status are shown in Table 2 and Figs 1 and 2. At the endpoint, there were 19 (59.4%)
Table 1. Comparions of longitudinal changes between FES patients and controls with respect to PM and other cognitive functions.
FES (n = 32) Controls (n = 17) #Comparison
between groups
At baseline At endpoint Statistics At baseline At endpoint Statistics Statistics
N % N % χ2 df p N % N % χ2 df p χ2 df p
Male sex 19 59.4 — — — — — 13 76.5 — — — — — 1.4 1 0.23
Mean SD Mean SD T/Z df P Mean SD Mean SD T/Z df P F/Z df P
Age (years) 26.2 8.1 — — — — — 25.5 5.6 — — — — — -0.5 —a 0.61
Education (years) 13.5 2.2 — — — — — 12.6 2.3 — — — — — -1.3 —a 0.20
HVLT-R 22.5 6.5 24.4 4.9 -2.5 31 0.02 26.8 5.3 27.3 4.4 -0.5 16 0.60 0.7 1, 44 0.40
CTT-1 56.9 17.4 51.6 14.1 1.8 31 0.09 43.3 15.1 35.4 9.0 1.8 16 0.09 1.2 1, 44 0.67
CTT-2 98.7 54.4 97.3 41.7 -0.2 —a 0.87 76.0 20.1 70.7 13.4 -0.9 —a 0.37 0.7 1, 44 0.41
SWCT 34.1 9.8 33.6 8.4 0.3 31 0.79 40.1 7.1 41.9 12.8 -0.6 —a 0.57 0.3 1, 44 0.58
VFL 2.6 1.0 1.8 1.5 -2.7 —a 0.007 3.6 1.7 4.1 2.0 -1.2 —a 0.24 8.0 1, 44 0.007
VFC 12.8 3.7 12.5 2.8 0.5 31 0.63 14.0 4.4 14.5 2.3 -0.5 16 0.62 1.5 1, 44 0.23
TBPM 7.9 5.2 9.3 5.3 -2.2 31 0.03 11.5 5.4 12.6 4.7 -0.7 —a 0.48 0.1 1, 44 0.74
EBPM 10.3 4.8 13.1 3.7 -3.1 31 0.004 16.5 2.3 15.7 3.6 -1.1 —a 0.26 8.8 1, 44 0.005
Note: (1) Results reported in this column (#) include the comparisons between the two groups regarding baseline age, gender, educational level and
longitudinal changes in PM and other cognitive functions. (2) For the repeated measures analysis of variance, only the effect of time*group interaction was
presented in the table.
a
= Wilcoxon signed rank test; TBPM = time-based prospective memory; EBPM = event-based prospective memory; HVLT-R = Hopkins Verbal Learning
Test-Revised Version; VFL = Verbal Fluency Test (letter test); VFC = Verbal Fluency Test (category test); CTT = Color Trails Test; SCWT = Stroop Color
Word Test;
doi:10.1371/journal.pone.0172114.t001
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remitters. Compared to non-remitters, remitters had a significantly shorter duration of illness,
a better performance on HVLT-R and TBPM, and lower PANSS “Anergia” score at baseline;
while having better performance on TBPM and EBPM, lower PANSS “Anergia” and “Thought
disturbance” scores at endpoint.
Table 2. Comparison between remitters and non-remitters with respect to demographic, clinical, PM and other cognitive variables at baseline and
endpoint.
At baseline At endpoint
Remitters
(n = 19)
Non-remitters
(n = 13)
Statistics Remitters
(n = 19)
Non-remitters
(n = 13)
Statistics
N % N % χ2 df p N % N % χ2 df p
Male sex 11 57.9 8 61.5 —b — 1.00 — — — — — — —
Inpatients 6 31.6 4 30.8 —b — 1.00 0 0.0 0 0.0 — — —
Medication status
Drug naïve 6 31.6 4 30.8 —b — 1.00 0 0.0 0 0.0 — — 0.00
risperidone 3 15.8 3 23.1 —b — 0.67 5 26.3 3 23.1 —b — 1.00
olanzapine 0 0.0 1 7.7 —b — 0.40 5 26.3 5 38.5 —b — 0.70
aripiprazole 7 36.8 3 23.1 —b — 0.47 9 47.4 5 38.5 —b — 0.73
quetiapine 2 10.5 0 0.0 —b — 0.50 0 0.0 0 0.0 — — 0.00
haloperidol 1 5.3 2 15.4 —b — 0.55 0 0.0 0 0.0 — — 0.00
Concomitant medications
Anticholinergics 0 0.0 0 0.0 — — — 6 31.6 6 46.2 —b — 0.47
Benzodiazepines 3 15.8 3 23.1 —b — 0.67 0 0.0 0 0.0 — — —
Mean SD Mean SD T/Z df P Mean SD Mean SD T/Z df P
Age (years) 25.2 8.5 27.6 7.5 -1.2 —a 0.23 — — — — — — —
Education (years) 13.1 2.4 14.0 1.7 -1.0 —a 0.32 — — — — — — —
Duration of illness (months) 8.1 4.6 20.0 11.1 -3.1 —a 0.002 — — — — — — —
PANSS subscales
Positive 27.3 6.9 29.8 6.4 -1.0 30 0.31 7.6 1.3 10.9 4.0 -3.2 —a 0.002
Negative 28.1 4.3 25.5 4.1 1.7 30 0.11 9.2 2.9 16.5 5.3 -3.8 —a <0.001
General 41.3 5.63 42.5 6.57 -0.6 30 0.58 18.4 2.3 23.2 4.8 -4.4 16.8 <0.001
PANSS cluster
Anergia 9.8 3.0 12.1 3.1 -2.1 30 0.04 5.1 1.4 7.8 2.6 -3.4 16.4 0.003
Thought disturbance 13.8 2.8 14.9 2.7 -1.2 30 0.26 4.4 0.8 6.3 2.4 -2.7 —a 0.02
Activation 7.2 1.7 6.2 2.4 1.4 30 0.19 3.1 0.5 3.9 1.5 -1.9 —a 0.22
Paranoid/belligerence 10.0 1.7 8.8 2.5 1.7 30 0.11 3.1 0.2 4.0 1.5 -2.4 —a 0.10
Depression 8.5 2.9 8.7 3.6 -0.2 30 0.85 4.6 1.5 4.8 2.0 -0.1 0.94
CPZeq (mg) 67.6 63.4 84.7 84.3 -0.5 —a 0.63 267.6 68.6 292.3 81.3 -0.7 —a 0.47
HVLT-R 24.6 5.8 19.3 6.3 2.5 30 0.02 25.5 4.9 22.9 4.7 1.6 30 0.13
CTT-1 58.1 19.8 55.2 13.7 0.5 30 0.64 50.6 14.1 53.0 14.6 -0.5 30 0.64
CTT-2 102.6 69.6 93.0 18.2 -0.3 —a 0.79 95.8 42.1 99.4 42.7 -0.6 —a 0.56
SWCT 35.3 10.5 32.5 8.9 0.8 30 0.44 35.7 6.3 30.5 10.3 1.8 30 0.09
VFL 2.4 0.9 3.0 1.1 -1.6 —a 0.12 2.0 1.5 1.4 1.4 -1.0 —a 0.33
VFC 13.7 4.0 11.6 3.0 1.6 30 0.12 12.9 2.7 11.9 2.9 1.0 30 0.32
TBPM 10.0 4.9 4.9 4.2 3.1 30 0.005 11.7 4.6 5.7 4.1 3.8 30 <0.001
EBPM 11.3 5.0 8.9 4.2 1.4 30 0.17 14.9 2.6 10.4 3.6 -3.3 —a <0.001
a
= Mann-Whitney U test;
b
= Fisher’s Exact Test; PANSS = Positive and Negative Syndrome Scale; TBPM = time-based prospective memory; EBPM = event-based prospective
memory; HVLT-R = Hopkins Verbal Learning Test-Revised Version; VFL = Verbal Fluency Test (letter test); VFC = Verbal Fluency Test (category test);
CTT = Color Trails Test; SCWT = Stroop Color Word Test; CPZeq = chlorpromazine equivalent
doi:10.1371/journal.pone.0172114.t002
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After controlling for age, gender, educational level, duration of illness and baseline EBPM
score, remitters still performed significantly better on EBPM (F(1, 25) = 12.2, p = 0.002) than
non-remitters at endpoint. However, the difference on TBPM (F(1, 25) = 3.1, p = 0.09) scores
between remitters and non-remitters disappeared after basic demographic characteristics and
the baseline assessments of cognitive functions were controlled for.
Fig 1. Time-based PM in FES patients and healthy controls.
doi:10.1371/journal.pone.0172114.g001
Fig 2. Event-based PM in FES patients and healthy controls.
doi:10.1371/journal.pone.0172114.g002
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Discussion
To the best of our knowledge, this is the first longitudinal, healthy controlled study on PM in
first-episode schizophrenia. The main finding is that EBPM significantly improved over time
in FES. Patients who remitted from their first-episode performed significantly better on EBPM
than non-remitters at 1-year follow-up suggesting that the improvement in EBPM perfor-
mance is probably associated with clinical remission in FES. These findings are consistent with
those of another longitudinal study that explored changes in PM in FES [39]. In that study,
patients’ EBPM performance gradually improved over time and eventually showed no signifi-
cant difference compared to healthy controls at the 1-year assessment. However, the control
group was not followed up and tested at 1-year, therefore the practice effect on the results
could not be excluded since TBPM deficit remained at the endpoint. In addition, PM was
assessed using a dual-task paradigm in the Cheung et al.’s study [39]; i.e., participants needed
to execute the PM task at a certain time or on the appearance of certain PM cues. In the present
study, ecologically valid paradigms were used. The Cambridge PM Task has the advantage of
simulating real-life situations and allowing participants to adopt strategies, such as taking
notes as reminders, to facilitate PM performance. Moreover, only the PANSS was used to mea-
sure psychopathology in the Cheung et al.’s study; in contrast, both the PANSS and remission
using the Andreasen’s definition [44, 45] were used in this study. Finally, types and doses of
antipsychotics were included in this study.
Neuroimaging studies found that the prefrontal cortex, particularly the lateral and medial
parts, plays an important role in generating PM [50–54]. In addition, the left parahippocampal
gyrus and the middle temporal gyrus are also activated during PM tasks in PET and fMRI
studies [50, 55–57]. Furthermore, both the prefrontal and temporal cortices have been
impaired in schizophrenia patients and their first-degree relatives [58, 59]. Taken together,
these findings suggest that impairments of PM might be an endophenotype of schizophrenia.
Endophenotypes are considered as “quantifiable biological variations or deficits that are types
of stable trait markers or indicators of presumed inherited vulnerability or liability to a disease”
[60]. However, the relative stability does not mean that the endophenotype could not be
changed in response to treatment. In clinical practice the primary focus is not to modify the
genetic variations associated with the endophenotype, but to “normalize” neural circuits and
activate collateral circuits [61], which may play a role in restoring neurocognitive and neuro-
physiological functions.
Findings on the trajectory of neurocognitive functioning in schizophrenia are inconsistent.
For example, verbal memory and learning were reported to be worsened, unchanged, or
improved across different studies [62–67]. In one study, there was a significant decline in Ver-
bal Learning and improvement on Reasoning/Problem Solving and Social Cognition at 2-year
follow-up in FES patients, but not in the control group, indicating a different neurocognitive
trajectory [68].
The inconsistency of the findings may reflect the involvement of different neural circuits in
cognitive processes. There have been several neuroimaging and neuropsychological studies on
the neural circuits possibly involved in TBPM and EBPM. A positron emission tomography
(PET) study has found the activation differences in rostral prefrontal cortex between TBPM
and EBPM tasks [56]. Specifically, when carrying out TBPM tasks, participants showed more
activation in areas of left superior frontal gyrus, right superior frontal gyrus, anterior medial
frontal lobe and anterior cingulate gyrus. When carrying out EBPM tasks, a different region in
the left superior frontal gyrus was found to be more active. Using the human lesion approach,
Volle et al. (2011) found that TBPM deficit in both words and pictures was specifically associ-
ated with lesions in the right polar prefrontal region, which was not due to impairments in
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basic neurocognitive functions. TBPM and EBPM may involve different frontal lobe process-
ing in FES; specifically, TBPM was found to be independently associated with CTT-2 and
WCST-CC, whereas EBPM was found to be predicted by WCST-PE [28].
It is thought that TBPM requires self-initiated retrieval and places greater demand on the
prefrontal cortex than EBPM [69]. This assumption was confirmed through moderator analy-
sis in a meta-analysis [70], showing that the variances were heterogeneous between TBPM and
EBPM; TBPM being more impaired than EBPM in schizophrenia. In a longitudinal study only
TBPM predicted remission after 8-week treatment pointing to the possible role of TBPM in
the short-term outcome of FES [71].
EBPM exhibited greater improvement in patients than in controls, while TBPM remained
impaired in patients, which is consistent with earlier findings [39]. In addition, the present
study found that remission is positively associated with better EBPM performance. These
results may have the following theoretical and clinical implications: (1) TBPM impairment is
relatively stable suggesting that it is more likely to be an endophenotype and associated to
genetic disposition; (2) EBPM could be potentially a neurocognitive marker of treatment
response in first episode schizophrenia.
The strengths of this study include the use of standardized assessment of PM, widely
accepted criteria of remission and standardized antipsychotic monotherapy. However, the
results should be interpreted with caution due to the following methodological limitations.
First, only a third of patients were drug-naive at baseline and some patients received anticho-
linergics or benzodiazepines. Second, the 1-year study period is relatively short; therefore, lon-
ger term emerging changes in cognitive components could not be detected. Third, the sample
size was relatively small, which limited the statistical power. Fourth, ideally a control group of
psychotropic drug-naive first-episode schizophrenia patients should be included in the one-
year follow-up. However, this would have been clinically impossible and unethical. Fifth, due
to logistic reasons, neuroimaging and electrophysiological measures were not included in this
study. Finally, the types and doses of antipsychotic medications used in the study period were
not fixed, which might have influenced the clinical outcomes. In order to examine the underly-
ing neural circuits associated with PM changes in schizophrenia, longitudinal studies with
fixed-dose antipsychotic monotherapy should be conducted coupled with extended follow-up
and neuroimaging and electrophysiological measures.
In conclusion, at 1-year follow-up, only EBPM improvement was associated with clinical
remission suggesting that it may be a potential neurocognitive marker for treatment response.
PM is likely to be a heterogeneous cognitive function both from theoretical and clinical view-
points in that TBPM appears to be a trait-related endophenotype, while EBPM may possibly
be a state-related component of PM.
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